Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.

Beshay LH, Makker J, Ahern S

Cureus27 Apr 2026

PMID42220693 (opens in a new tab)PMCIDPMC13215789 (opens in a new tab)DOI10.7759/cureus.107836 (opens in a new tab)PepBankPUB-42220693
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Medullary thyroid cancer (MTC) stems from thyroid parafollicular C cells and is considered a rare type of neuroendocrine tumor. It can be inherited as part of syndromes, such as familial medullary thyroid cancer (FMTC) and multiple endocrine neoplasia type 2 (MEN 2), or it can arise sporadically. GLP-1 receptor agonist drugs (GLP1 RA), like semaglutide and tirzepatide, carry an FDA black box warning against using them in patients who have a prior history or a family history of MTC or MEN2. This recommendation stems from rodent studies showing thyroid C-cell tumors. Current studies have not confirmed an association between GLP1RAs and risk of differentiated thyroid cancer in human studies. In addition, there is no consensus on screening or evaluating patients for thyroid cancer prior to or during treatment with GLP1 RA. Here, we report a case of mixed medullary and papillary thyroid carcinoma newly diagnosed in a 68-year-old female on tirzepatide for type 2 diabetes who presented with a neck mass.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 68-year-old woman taking tirzepatide for type 2 diabetes was newly diagnosed with mixed medullary and papillary thyroid carcinoma after presenting with a neck mass.

    In plain wordsOne 68-year-old woman taking tirzepatide for type 2 diabetes was found to have a mixed type of thyroid cancer; the case does not show cause.

    Peptide
    Tirzepatide
    Outcome
    Not applicableMixed medullary and papillary thyroid carcinoma
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we report a case of mixed medullary and papillary thyroid carcinoma newly diagnosed in a 68-year-old female on tirzepatide for type 2 diabetes who presented with a neck mass.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.